Related Experiment Video
Updated: Jun 2, 2026
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
[SDHB expression in Warthin's tumour]
Beatriz Vera-Sirera1, Judith Pérez-Rojas, Cecilia López-Valdivia
1Departamento de Estomatología, Universidad de Valencia, Valencia, España. vera_fra@gva.es
Acta Otorrinolaringologica Espanola
|May 13, 2011
Summary
Succinic dehydrogenase subunit B (SDHB) is highly expressed in Warthin's tumours, indicating oncocytic changes are not linked to mitochondrial complex II defects. This strong SDHB reactivity serves as a novel marker for oncocytic changes in Warthin's tumours.
Area of Science:
- Biochemistry
- Oncology
- Pathology
Context:
- Warthin's tumour is a common benign salivary gland neoplasm.
- Oncocytic changes are a hallmark of Warthin's tumour.
- Succinic dehydrogenase subunit B (SDHB) is a key enzyme in mitochondrial complex II.
Purpose:
- To investigate the expression of SDHB in Warthin's tumours.
- To determine the relationship between SDHB expression and oncocytic changes.
- To assess SDHB as a potential diagnostic marker.
Summary:
- Immunohistochemical analysis of SDHB in ten Warthin's tumours revealed strong reactivity in the oncocytic epithelial component.
- SDHB expression was consistently high in oncocytic cells, irrespective of patient age, smoking habits, or tumour bilaterality.
- One tumour showed SDHB negativity in areas of squamous metaplasia.
Impact:
- Oncocytic changes in Warthin's tumour are not associated with impaired mitochondrial complex II function.
- Strong SDHB reactivity is identified as a new immunohistochemical marker for oncocytic changes in Warthin's tumour.
- These findings offer novel insights into the pathobiology of Warthin's tumour.
